Botanix Investor Centre

Botanix Pharmaceuticals is a clinical stage synthetic cannabinoid pharmaceutical company with a targeted pipeline of dermatology and antimicrobial products. Our goal is to unlock the true potential of synthetic cannabinoids for people around the world, with an evidence-first approach. Our shareholders are valued partners in our Company, so we invite you to explore our Investor Centre, subscribe to our email updates and we will keep you updated with our progress.

Share price


Change

December 9, 2019
September 17, 2019
January 31, 2019
November 15, 2018
August 13, 2018
April 9, 2018
November 13, 2017

Latest video

CBD oil kills gonorrhoea bacteria, potential for ‘much-needed new class of antibiotics’

Groundbreaking new research has found synthetic cannabidiol…

Qld researchers on how cannabis could be used to fight superbug

Queensland researchers are studying a component of medicinal…

Journal article | “The antimicrobial potential of cannabidiol”

An important research project testing the targeted capabilities…

Oxford research tackles threat of antibiotic resistance

Oxford University is opening a new research institute dedicated…

UQ media release | Research establishes antibiotic potential for cannabis molecule

Synthetic cannabidiol, better known as CBD, has been shown for…

Superbugs will kill 22,000 Australians annually by 2040; but these stocks are trying to stop that

Superbugs were this week labelled as “the next great health…

Antibiotic resistance: a matter of time

"Is this just a projection...?"  The narrator of this…

Botanix Pharmaceuticals updates on meeting with FDA

AusBiotech's BiotechDispatch featured our BTX 1801 antimicrobial…

Interested in investing? Check out our latest investor presentation.

Sign up to receive our latest news.

Processing...
Thank you! Your subscription has been confirmed. You'll hear from us soon.
ErrorHere